DOCSLIB.ORG

Release of Soluble CD40L from Platelets Is Regulated by Glycoprotein Iib/Iiia and Actin Polymerization Mark I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Release of Soluble CD40L from Platelets Is Regulated by Glycoprotein Iib/Iiia and Actin Polymerization Mark I View metadata, citation and similar papers at core.ac.uk brought to you by CORE Journal of the American College of Cardiology providedVol. by 43,Elsevier No. 12,- Publisher 2004 Connector © 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.12.055 Platelet GP IIb/IIIa Inhibition Release of Soluble CD40L From Platelets Is Regulated by Glycoprotein IIb/IIIa and Actin Polymerization Mark I. Furman, MD, FACC,*† Lori A. Krueger, BA, MLT, ART,* Matthew D. Linden, PHD,* Marc R. Barnard, MS,* Andrew L. Frelinger III, PHD,* Alan D. Michelson, MD* Worcester, Massachusetts OBJECTIVES The purpose of this study was to examine the effects of glycoprotein (GP) IIb/IIIa antagonists (abciximab, eptifibatide, and tirofiban) and other inhibitors on translocation of CD40L from intraplatelet stores to the platelet surface and on the release of soluble CD40L (sCD40L) from platelets. BACKGROUND CD40L is a proinflammatory and prothrombotic ligand in the tumor necrosis factor family. METHODS Platelet surface CD40L was measured by flow cytometry, and sCD40L was measured by enzyme-linked immunosorbent assay. RESULTS Translocation of CD40L from intraplatelet stores to the platelet surface was not inhibited by GP IIb/IIIa antagonists. However, release of sCD40L from the surface of activated platelets was inhibited by GP IIb/IIIa antagonists in a dose-dependent manner, in concert with inhibition of PAC1 binding to platelets (a surrogate marker for fibrinogen binding). Release of sCD40L from activated platelets was also markedly reduced in Glanzmann platelets (deficient in GP IIb/IIIa). Ethylenediaminetetraacetic acid was an effective inhibitor of sCD40L release, but only when added before platelet activation. Both cytochalasin D (an inhibitor of actin polymerization) and GM6001 (an inhibitor of matrix metalloproteinases [MMPs]) inhibited the release of sCD40L from platelets when added before, as well as 3 min after, platelet activation. However, neither cytochalasin D nor GM6001 affected translocation of CD40L to the platelet surface. CONCLUSIONS The GP IIb/IIIa antagonists inhibit release of sCD40L from activated platelets. Release of sCD40L from platelets is regulated, at least in part, by GP IIb/IIIa, actin polymerization, and an MMP inhibitor-sensitive pathway. In addition to their well-characterized inhibition of platelet aggregation, GP IIb/IIIa antagonists may obviate the proinflammatory and pro- thrombotic effects of sCD40L. (J Am Coll Cardiol 2004;43:2319–25) © 2004 by the American College of Cardiology Foundation In addition to their well-known function in hemostasis and preformed intraplatelet stores of CD40L to the platelet thrombosis, platelets play an important role in inflammation surface within seconds of activation in vitro and in the (1). Platelets contain a variety of inflammatory modula- presence of thrombus formation in vivo. Furthermore, tors—including CD40 ligand (CD40L, CD154), platelet- platelet surface CD40L interacts with endothelial cell derived growth factor, platelet factor 4, RANTES (regu- CD40 to induce a thromboinflammatory reaction of endo- lated upon activation, normal T-cell expressed and thelial cells (3). Activated platelets also release large amounts of soluble CD40L (sCD40L) over a period of See page 2326 minutes to hours (4–6). Indeed, platelets appear to be the predominant source of circulating sCD40L (5). The secreted), thrombospondin, and transforming growth factor sCD40L released from platelets during thrombosis has beta—that are released upon platelet activation. Atheroscle- three reported functions (7): 1) induction of the production rosis is a chronic inflammatory disease, and the CD40/ and release of proinflammatory cytokines from vascular cells CD40L interaction has a central role in the pathogenesis of and of matrix metalloproteinases (MMPs) from resident atherosclerosis (2). cells in the atheroma (although not all studies agree on this CD40L, a member of the tumor necrosis factor family, is point [5]); 2) stabilization of arterial thrombi (8); and 3) not expressed on the resting platelet surface. However, inhibition of re-endothelialization of injured blood vessels Henn et al. (3) demonstrated that platelets translocate (9). In the present study, we examined the effects of GP From the *Center for Platelet Function Studies and †Division of Cardiovascular IIb/IIIa antagonists (abciximab, eptifibatide, and tirofiban) Medicine, Departments of Pediatrics and Medicine, University of Massachusetts and other inhibitors on the translocation of CD40L from Medical School, Worcester, Massachusetts. Supported in part by Eli Lilly & Co. Manuscript received July 14, 2003; revised manuscript received December 16, intraplatelet stores to the platelet surface and on the release 2003, accepted December 23, 2003. of sCD40L from platelets. 2320 Furman et al. JACC Vol. 43, No. 12, 2004 Regulation of CD40L Release From Platelets June 16, 2004:2319–25 (Polysciences, Eppelheim, Germany) for 10 min at 22°C. Abbreviations and Acronyms Samples labeled with 24-31 were then washed by centrifu- EDTA ϭ ethylenediaminetetraacetic acid gation at 1,200 g for 7 min, and the formalin supernatant ELISA ϭ enzyme-linked immunosorbent assay was aspirated. The platelet pellet was then resuspended in ϭ FITC fluorescein isothiocyanate HT buffer containing the GP IIIa-specific FITC- GP ϭ glycoprotein ϭ conjugated monoclonal antibody Y2/51 (DAKO, Carpin- HT HEPES Tyrode’s buffer ␮ MMPs ϭ matrix metalloproteinases teria, California) 0.5 g/ml (or, for Glanzmann samples, PCI ϭ percutaneous coronary intervention the GPIX-specific PerCP-conjugated monoclonal antibody PE ϭ phycoerythrin Beb1 [Becton Dickinson] 1.25 ␮g/ml) and incubated at ϭ PerCP peridinin chlorophyll protein 22°C for 10 min. Samples were then diluted in 1% formalin PRP ϭ platelet-rich plasma sCD40L ϭ soluble CD40 ligand until analysis by flow cytometry. Flow cytometry was per- formed in a FACSCalibur (Becton Dickinson) with stan- dard filter configuration and Cell Quest software. Platelets METHODS were identified by their characteristic forward and orthog- onal light scatter properties and by labeling with a platelet- Blood collection. This study was approved by the institu- specific monoclonal antibody (FITC-Y2/51, PerCP-RUU- tional review board of the University of Massachusetts 7F12, or PerCP-Beb1). Platelet surface CD40L and Memorial Health Care, and subjects gave written informed activated GP IIb/IIIa was measured by mean fluorescence consent. Peripheral blood was collected from healthy donors intensity (PE and FITC, respectively). Neither Y2/51 nor or patients with Glanzmann thrombasthenia (10) into RUU-7F12 block the binding of abciximab, eptifibatide, endotoxin-free 3.2% sodium citrate Vacutainer tubes (Bec- tirofiban, or PAC1. ton Dickinson, San Jose, California), after discarding the Enzyme-linked immunosorbent assay (ELISA). Platelet first 2 ml of drawn blood. No donor or patient had received counts in PRP were normalized to 300,000 platelets per ␮l. any drug known to affect platelet function (including aspi- The PRP was then incubated (22°C, 20 min) with various rin, cyclooxygenase inhibitors, statins) within the previous concentrations of a GP IIb/IIIa antagonist, EDTA 5 mM, 10 days. Platelet-rich plasma (PRP) was prepared by cen- GM6001 30 ␮M, cytochalasin D 60 ␮M, or HT buffer trifuging the blood at 150 g for 12 min at 22°C. alone. Samples were incubated (37°C, 1 h) with or without Flow cytometry. The PRP was diluted 1:5 (to prevent 50 ␮M isoTRAP. In some experiments, EDTA 5 mM, platelet aggregation) with modified HEPES Tyrode’s(HT) GM6001 30 ␮M, or cytochalasin D 60 ␮M was added 3 ␮ buffer (NaCl 137 mM, KCl 2.8 mM, MgCl2 1mM, min after the addition of the 50 M isoTRAP. After NaHCO3 12 mM, Na2HPO4 0.4 mM, glucose 5.5 mM, activation, the samples were centrifuged (8,000 g, 3 min, HEPES 10 mM, pH 7.4) and (to prevent Fc-mediated 22°C), the supernatants were transferred to a clean tube and effects) incubated at 22°C for 10 min with the Fc␥RIIa centrifuged again (8,000 g, 3 min, 22°C), and the subse- (CD32) blocking antibody IV.3 (Medarex, Princeton, New quent supernatants were transferred to a clean tube. These Jersey) 2.5 ␮g/ml. The PRP was then incubated at 22°C for supernatants were then immediately tested for sCD40L by 20 min with either HT buffer alone, abciximab 6.4 ␮g/ml, ELISA (Bender MedSystems, San Bruno, California). The eptifibatide 1.0 ␮g/ml, tirofiban 50 ng/ml, ethylenediamine- ELISA was set up according to the package insert except tetraacetic acid (EDTA) 5 mM, GM6001 (also known as that plasma samples were diluted 1:1 (50 ␮l:50 ␮l) with Galardin, an inhibitor of MMPs [11]) (Calbiochem, San assay buffer. The average of duplicate samples was recorded. Diego, California) 30 ␮M, or cytochalasin D (an inhibitor To determine the amount of released sCD40L, the of actin polymerization [12]) (Sigma, St. Louis, Missouri) sCD40L concentration of samples without added isoTRAP 60 ␮M. (Assays with GM6001 and cytochalasin D included was subtracted from the sCD40L concentration of samples 0.3% dimethyl sulfoxide.) Samples were then incubated with added isoTRAP. The range of 0.33 to 4.84 ng/ml in with or without 50 ␮M iso(S)FLLRN (iso-thrombin re- the background sCD40L of our normal donors and Glanz- ceptor activating peptide) (Multiple Peptide Systems, San mann thrombasthenia donors is consistent with the Diego, California) and with a saturating concentration of sCD40L range of 0.03 to 4.0 ng/ml obtained from a panel either the CD40L-specific phycoerythrin (PE)-conjugated of 40 healthy donors (Bender MedSystems, product insert). monoclonal antibody 24-31 (Ancell, Bayport, Minnesota) This normal variability in the background sCD40L of both (or the same concentration of PE-conjugated mouse isotype the normal donors and the Glanzmann thrombasthenia control IgG1 [Pharmingen, San Diego, California]) for 1 h donors does not detract from our conclusions, because each at 37°C or a cocktail of the activated GP IIb/IIIa-specific donor and patient acted as his or her own control.
Load more

Recommended publications
  • Safety of Tirofiban for Patients with Acute Ischemic Stroke in Routine Clinical Practice
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 10: 169-174, 2015 Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice YUAN-QUN ZHU1, YAN-JUN ZHANG2, HAI-LIN RUAN3, QING LIU2, QIN ZHAN2 and QIONG LI2 1Department of Neurology, Liuzhou Worker's Hospital, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005; 2Department of Geriatrics, People's Hospital of Zhengzhou, Zhengzhou, Henan 450003; 3Department of Emergency, Liuzhou Worker's Hospital, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, P.R. China Received April 11, 2014; Accepted December 8, 2014 DOI: 10.3892/etm.2015.2495 Abstract. The aim of the present study was to investigate the Introduction safety of tirofiban alone and in combination with various treat- ments in acute ischemic stroke (AIS). A total of 120 patients Acute ischemic stroke (AIS) is a common cause of morbidity with AIS were included in the study, and these patients were and mortality worldwide. Thrombolysis with recombinant divided into three treatment groups: Group A (tirofiban alone, tissue plasminogen activator (rtPA) is the only proven beneficial n=68), group B (tirofiban plus thrombolytic therapy, n=26), therapy in AIS, and this is received by <2% of patients (1). The and group C (tirofiban as a ‘bridging therapy’, n=26). Risk inaccessibility of this treatment to the majority of patients is due factors, stroke severity, initial imaging, treatment regimens, to a number of factors: A lack of adequate transport facilities complications and long‑term outcomes were analyzed. In and infrastructure, including facilities for thrombolysis in most total, eight patients (6.7%) [six patients (23.1%) in group B centers; the high cost of tPA; and a lack of awareness among and two patients (7.7%) in group C] had hemorrhage during the public and doctors (2).
    [Show full text]
  • Summary of the Product Characteristics
    Tirofiban hydrochloride Hikma Pharma GmbH SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT <TIROFIBAN>® *50 micrograms/mL Solution for infusion <TIROFIBAN>® *250 micrograms/mL Concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION <TIROFIBAN> Solution: 1 ml of solution for infusion contains 56 micrograms of tirofiban hydrochloride monohydrate which is equivalent to 50 micrograms Tirofiban. This medicinal product contains 31 mmol (or 715 mg) sodium per bag (250 ml). To be taken into consideration by patients on a controlled sodium diet. <TIROFIBAN> Concentrate: 1 ml of concentrate for solution for infusion contains 281 micrograms of tirofiban hydrochloride monohydrate which is equivalent to 250 micrograms Tirofiban. 50 ml of concentrate for solution for infusion contains 14,05 mg of tirofiban hydrochloride monohydrate which is equivalent to 12,5 mg Tirofiban. This medicinal product contains less than 1 mmol sodium (23 mg) per vial (50 ml), i.e. essentially ‘sodium- free’. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM <TIROFIBAN> Solution: Solution for Infusion (250 ml bag) A clear, colourless solution. <TIROFIBAN> Concentrate: Concentrate for solution for infusion. A clear, colourless concentrated solution. * in the following document the abbreviated terms detailed below are used. • <TIROFIBAN> means <TIROFIBAN> Solution for Infusion or <TIROFIBAN> Concentrate for Solution for Infusion. • <TIROFIBAN> Solution will be used when referring to <TIROFIBAN> Solution for Infusion
    [Show full text]
  • The Role of Low-Molecular-Weight Heparin in the Management of Acute Coronary Syndromes Marc Cohen, MD, FACC Newark, New Jersey
    CORE Metadata, citation and similar papers at core.ac.uk Provided by ElsevierJournal - ofPublisher the American Connector College of Cardiology Vol. 41, No. 4 Suppl S © 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/S0735-1097(02)02901-7 The Role of Low-Molecular-Weight Heparin in the Management of Acute Coronary Syndromes Marc Cohen, MD, FACC Newark, New Jersey A substantial number of clinical studies have consistently demonstrated that low-molecular- weight heparin (LMWH) compounds are effective and safe alternative anticoagulants to unfractionated heparins (UFHs). They have been found to improve clinical outcomes in acute coronary syndromes and to provide a more predictable therapeutic response, longer and more stable anticoagulation, and a lower incidence of UFH-induced thrombocytopenia. Of the several LMWH agents that have been studied in large clinical trials, including enoxaparin, dalteparin, and nadroparin, not all have shown better efficacy than UFH. Enoxaparin is the only LMWH compound to have demonstrated sustained clinical and economic benefits in comparison with UFH in the management of unstable angina/ non–ST-segment elevation myocardial infarction (NSTEMI). Also, LMWH appears to be a reliable and effective antithrombotic treatment as adjunctive therapy in patients undergoing percutaneous coronary intervention. Clinical trials with enoxaparin indicate that LMWH is effective and safe in this indication, with or without the addition of a glycoprotein IIb/IIIa inhibitor. The efficacy demonstrated by enoxaparin in improving clinical outcomes in unstable angina/NSTEMI patients has led to investigations of its role in the management of ST-segment elevation myocardial infarction.
    [Show full text]
  • Code ATC B01 : Antithrombotiques
    Département fédéral de l'économie, de la formation et de la recherche DEFR Office fédéral pour l'approvisionnement économique du pays OFAE domaine produits thérapeutiques 18 décembre 2020 Code ATC B01 : antithrombotiques Rapport sur les risques de de sous-approvisionne- ment en antithrombotiques (code ATC B01) : première évaluation 2019 Rapport sur les risques de sous-approvisionnement en antithrombotiques Table des matières 1. Résumé ........................................................................................................................................... 4 2. Objectif ............................................................................................................................................. 5 3. Analyse ............................................................................................................................................ 5 3.1. Procédure ................................................................................................................................ 5 3.2. Bases moléculaires de l’hémostase ........................................................................................ 6 3.3. Thrombose ............................................................................................................................... 6 4. Prophylaxie et traitement des thromboses et des thromboembolies (antagonistes de la vitamine K et anticoagulants oraux directs, code ATC B01AA) ................................................................................ 7 4.1 Utilisation et
    [Show full text]
  • GP Iib/Iiia Adult Cardiology Treatment Dosing and Monitoring Guidelines
    GP IIb/IIIa Inhibitor Adult Cardiology Treatment Dosing and Monitoring Guidelines During times of eptifibatide shortage, the following guidance is available for tirofiban usei Eptifibatide (Integrilin®) Tirofiban (Aggrastat®) Dosing Loading dose: 180 mcg/kg IV bolus (max: 22.6 mg) Loading dose: 25 mcg/kg IV over 5 minutes ii ACS Maintenance infusion: 2 mcg/kg/minute (max: 15 mg/hr) up to 72 hours Maintenance infusion: 0.15 mcg/kg/minute continued for up to 18 (until discharge or CABG surgery) hours st 1 Loading dose: 180 mcg/kg IV bolus (max: 22.6 mg) Loading dose: 25 mcg/kg IV over 5 minutes ii PCI Maintenance infusion: 2 mcg/kg/minute (max: 7.5 mg/hr) continued for Maintenance infusion: 0.15 mcg/kg/minute continued for up to 18 up to 18 to 24 hours hours 2nd loading dose: 180 mcg/kg IV bolus (max: 22.6 mg) should be administered 10 minutes after the first bolus Dose Adjustment For CrCl ≤ 50 mL/minute: For CrCl ≤ 60 mL/minute: 1st loading dose: 180 mcg/kg IV bolus (max: 22.6 mg) Loading dose: 25 mcg/kg IV over 5 minutes Maintenance infusion: 2 mcg/kg/minute (max 7.5 mg/hr) Maintenance infusion: 0.075 mcg/kg/minute continued for up to 18 2nd loading dose (if PCI): 180 mcg/kg IV bolus (max: 22.6 mg) should be hours administered 10 minutes after the first bolus For end-stage renal disease: CONTRAINDICATED Contraindications − Severe hypersensitivity reaction to eptifibatide − Severe hypersensitivity reaction to tirofiban − History of bleeding diathesis or evidence of active abnormal bleeding − A history of thrombocytopenia following prior
    [Show full text]
  • Summary of the Product Characteristics
    Tirofiban hydrochloride Welding GmbH & Co.KG 1.3 Product Information SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT <TIROFIBAN>® *50 micrograms/mL Solution for infusion <TIROFIBAN>® *250 micrograms/mL Concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION <TIROFIBAN> Solution: 1 ml of solution for infusion contains 56 micrograms of Tirofiban hydrochloride monohydrate which is equivalent to 50 micrograms Tirofiban. This medicinal product contains 31 mmol (or 715 mg) sodium per bag (250 ml). To be taken into consideration by patients on a controlled sodium diet. <TIROFIBAN> Concentrate: 1 ml of concentrate for solution for infusion contains 281 micrograms of Tirofiban hydrochloride monohydrate which is equivalent to 250 micrograms Tirofiban. 50 ml of concentrate for solution for infusion contains 70.2514,05 mg of Tirofiban hydrochloride monohydrate which is equivalent to 62.512,5 mg Tirofiban. This medicinal product contains less than 1 mmol sodium (23 mg) per vial (50 ml), i.e. essentially ‘sodium- free’. For excipients, see section 6.1. 3 PHARMACEUTICAL FORM <TIROFIBAN> Solution: Solution for Infusion (250 ml bag) A clear, colourless solution. <TIROFIBAN> Concentrate: Concentrate for solution for infusion. A clear, colourless concentrated solution. * in the following document the abbreviated terms detailed below are used. • <TIROFIBAN> means <TIROFIBAN> Solution for Infusion or <TIROFIBAN> Concentrate for Solution for Infusion. • <TIROFIBAN> Solution will be used when referring to <TIROFIBAN>
    [Show full text]
  • NDA 20-718/S-025 Page 2 of 18 Integrilin (Eptifibatide)
    NDA 20-718/S-025 Page 2 of 18 Integrilin (eptifibatide) Injection For Intravenous Administration DESCRIPTION Eptifibatide is a cyclic heptapeptide containing six amino acids and one mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L--aspartyl-L-tryptophyl-L-prolyl-L- cysteinamide,cyclic (1→6)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Integrilin (eptifibatide) Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use. Each 10-mL vial contains 2 mg/mL of eptifibatide and each 100-mL vial contains either 0.75 mg/mL of eptifibatide or 2 mg/mL of eptifibatide. Each vial of either size also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. CLINICAL PHARMACOLOGY Mechanism of Action. Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. Pharmacodynamics. Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5.0 µg/kg/min.
    [Show full text]
  • Ticagrelor Versus Clopidogrel and Eptifibatide Bolus in Patients with Stable Or Unstable Angina Undergoing Coronary Intervention: a Randomized Pharmacodynamic Study
    Ticagrelor versus Clopidogrel and Eptifibatide Bolus in Patients with Stable or Unstable Angina Undergoing Coronary Intervention: A Randomized Pharmacodynamic Study Study Protocol & Statistical Analysis Plan NCT02925923 December 17, 2019 Massoud A. Leesar, M.D., Principal Investigator University of Alabama at Birmingham Birmingham, AL 35294 Ticagrelor versus Clopidogrel and Eptifibatide Bolus in Patients with Stable or Unstable Angina Undergoing Coronary Intervention: A Randomized Pharmacodynamic Study Moazez Marian, PhD, Olseun Alli, MD, Firas Al soliman, MD; Mark Sasse, MD, Arka Chatterjee, MD, Himanshu Aggarwal, MD, Andrew Kurtlinsky, MD Massoud Leesar, MD Division of Cardiology, UAB Center for Thrombosis Research, University of Alabama, Birmingham Address for Correspondence: Massoud A. Leesar, MD Division of Cardiology University of Alabama-Birmingham Birmingham, AL, 35294 Telephone: (205) 975-0816 E-mail: [email protected] 2 In the Ad Hoc percutaneous coronary intervention (PCI) study (Presented at the SCAI meeting, 2015), 100 patients with troponin-negative acute coronary syndrome were randomized to receive ticagrelor (180mg loading dose [LD] and 90mg after 12hr) or clopidogrel (600mg LD and 75 mg TM after 12 h) with aspirin 75–100mg daily. P2Y12 reactivity unit [PRU] using VerifyNow assay was measured pre-LD, and at 0.5, 2 and 8 h post LD. At 2 h, PRU was lower with ticagrelor vs. clopidogrel (98.4 ± 95.4 vs. 257.5 ± 74.5, respectively; p<0.001). PRU diverged as early as 0.5 h post ticagrelor LD and there was a significant reduction in the PRU level with ticagrelor. The rate of high on-treatment PRU level was significantly reduced with ticagrelor compared with clopidogrel at 2 h (13.3% vs.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH Pr AGGRASTAT® tirofiban hydrochloride injection 12.5 mg / 250 mL tirofiban (5 mg / 100 mL in bags of 250 mL) Sterile Solution for Intravenous Infusion only Platelet aggregation inhibitor Cipher Pharmaceuticals Inc. Date of Revision: 2345 Argentia Road, Suite 100A July 24, 2018 Mississauga, Ontario L5N 8K4 Submission Control No.: 218105 AGGRASTAT® - Product Monograph Page 1 of 31 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS ................................................................................................. 11 DOSAGE AND ADMINISTRATION ............................................................................. 12 OVERDOSAGE ................................................................................................................ 17 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 17 STORAGE AND STABILITY ........................................................................................
    [Show full text]
  • Platelet Glycoprotein Iib/Iiia Integrin Blockade with Eptifibatide in Coronary Stent Intervention the ESPRIT Trial: a Randomized Controlled Trial
    ORIGINAL CONTRIBUTION Platelet Glycoprotein IIb/IIIa Integrin Blockade With Eptifibatide in Coronary Stent Intervention The ESPRIT Trial: A Randomized Controlled Trial J. Conor O’Shea, MD Context The Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Gail E. Hafley, MS Therapy (ESPRIT) trial showed the efficacy of adjunctive, double-bolus eptifibatide therapy Sally Greenberg, PhD in reducing ischemic complications of nonurgent coronary stent implantation at 48 hours and at 30 days. Vic Hasselblad, PhD Objective To determine whether the beneficial effects of eptifibatide persist at 6 months Todd J. Lorenz, MD after treatment. Michael M. Kitt, MD Design Follow-up study of a randomized, double-blind, placebo-controlled, crossover- permitted trial conducted from June 1999 through February 2000. John Strony, MD Setting Ninety-two tertiary care centers in the United States and Canada. James E. Tcheng, MD Participants A total of 2064 patients scheduled to undergo nonurgent percutane- for the ESPRIT Investigators ous coronary intervention with stent implantation. ORONARY THROMBOSIS IS CEN- Intervention Patients were randomly assigned to receive placebo or eptifibatide (two tral to the pathogenesis of ath- 180-µg/kg boluses 10 minutes apart and continuous infusion of 2.0 µg/kg per minute), started immediately before stent implantation and continued for 18 to 24 hours. Com- erosclerosis, acute myocar- plete follow-up data were available for 988 (95.0%) of 1040 patients given eptifi- dial infarction (AMI), acute batide and 977 (95.4%) of 1024 patients given placebo. Ccoronary syndromes, and ischemic com- Main Outcome Measures Composite rates of death or myocardial infarction (MI); plications of percutaneous coronary in- 1 death, MI, or target vessel revascularization; and their individual components 6 months tervention (PCI).
    [Show full text]
  • Intravenous Tirofiban Therapy for Patients with Capsular Warning Syndrome
    Open access Original article Stroke Vasc Neurol: first published as 10.1136/svn-2018-000163 on 9 January 2019. Downloaded from Intravenous tirofiban therapy for patients with capsular warning syndrome Wei Li, Ya Wu, Xiao-Shu Li, Cheng-Chun Liu, Shu-Han Huang, Chun-Rong Liang, Huan Wang, Li-Li Zhang, Zhi-Qiang Xu, Yan-Jiang Wang, Meng Zhang To cite: Li W, Wu Y, Li X-S, et al. ABSTRACT Although CWS occurs in only about 1.5% Intravenous tirofiban therapy for Background Capsular warning syndrome (CWS) is defined of patients with transient symptoms, the risk patients with capsular warning as recurrent episodes of transient ischaemic attacks ≥3 syndrome. of developing into a permanent deficit is high Stroke and Vascular times during a short time frame. There is no effective 4 Neurology 2019;4: e000163. and often with poor prognosis. Moreover, therapy to stop these attacks. We, herein, report our doi:10.1136/svn-2018-000163 the frequently recurrent attacks cause signif- experience of using intravenous tirofiban to treat CWS. icant disability and great anxiety to patients ► Additional material is Methods All patients with CWS in our hospital from who experience these episodes. Different published online only. To view January 2013 to September 2017 were reviewed. please visit the journal online Patients in tirofiban group (T-group) were treated by therapies have been proposed, including anti- (http:// dx. doi. org/ 10. 1136/ svn- intravenous tirofiban at 0.4 μg/kg/min for 30 min followed coagulation, antiplatelet therapies and even 2018- 000163). by 0.1–0.15 µg/kg/min infusion.
    [Show full text]